Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
Anderson TS, Ayanian JZ, Souza J, Landon BE.. Shen KN, et al. Circulation. 2021 Sep 10. doi: 10.1161/CIRCULATIONAHA.121.055953. Online ahead of print. Circulation. 2021. PMID: 34503349. Clinical Trial.